|
Top-Line Results By Year-End As the industry prepared for the first deluge of American Society of Clinical Oncology (ASCO) data Thursday night, cancer drug company Allos Therapeutics Inc. managed to capture a little attention of its own early in the day by reporting promising interim data from...
ZIOPHARM Oncology Inc (NASDAQ:ZIOP), a biopharmaceutical company, reported on 13 May the receipt of Notices of Allowance from the US Patent and Trademark Office for patent applications numbered 11/252,966 and 11/349,043 covering darinaparsin. The company
The Orphan Drug Act gives pharma companies an extra incentive to work on smaller-market drugs. ... Sometimes, not very often, companies do things that they know won't make them a lot of money, but that will be good for at least a small group of people. Ziopharm Oncology...
Ziopharm Oncology has presented positive data from a Phase II study of darinaparsin, the company's novel organic arsenic compound, in advanced hematological malignancies. ... A total of 40 patients with a variety of hematological malignancies, including leukemias and...
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today Dr. Jonathan Lewis, Chief Executive Officer, will present at the 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008 at 2:00 p.m. GMT (9:00 a.m. ET) at the Four Seasons Hotel Park Lane in London, United Kingdom.
9:41AM Quantum Fuel announces mgmt stock purchases 0.75 +0.01 : Co announces that a majority of its executive management team, including CEO and President Alan Niedzwiecki; CFO Brian Olson; Dale Rasmussen, Chairman of the Board; and other board members, have purchased...
BETHESDA, Md.----ZIOPHARM Oncology, Inc. announced today that it presented promising early data from a Phase Ib study of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the 6th International Symposium on Targeted Anticancer Therapies held in Bethesda,...
